First in-human evaluation of CO-1686 - Dr. Parneet Cheema

Description: For more updates visit

Video update from the 15th World Conference on Lung Cancer. First in-human evaluation of CO-1686, an irreversible, highly, selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).
Shared By : oncologyeducation
Posted on : 11/05/13
Added : 4 years ago
Category : General

More From oncologyeducation

Nothing found.